Company GlycoNex Incorporation

Equities

4168

TW0004168000

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-05 pm EDT			5-day change	1st Jan Change
24.9 ^TWD	-1.19%		-2.35%	-16.30%

Mar. 19	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

TWD in Million	2022	Weight	2023	Weight	Delta
Antibody New Drug 100.0 %	30	100.0 %	3	100.0 %	-91.55%

TWD in Million	2022	Weight	2023	Weight	Delta
Japan 63.3 %	19	64.1 %	2	63.3 %	-91.65%
Taiwan 36.7 %	0	1.6 %	1	36.7 %	+99.36%

Managers	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	06-12-31
Tong Hsuan Chang FOU	Founder	-	01-01-31
Dih Fen Wu DFI	Director of Finance/CFO	-	09-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	12-11-11

Members of the board	Title	Age	Since
Kao Chung Tsai BRD	Director/Board Member	62	-
Tong Hsuan Chang FOU	Founder	-	01-01-31
Ling-Chun Tsai BRD	Director/Board Member	-	12-05-24
Hsiu E. Su BRD	Director/Board Member	-	-
Tseng-Fu Chen BRD	Director/Board Member	-	12-05-24
Cai Qing Hong BRD	Director/Board Member	-	-
Zong Zheng Wu BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	108,640,100	89,098,133 ( 82.01 %)	0	82.01 %

Name	Equities	%	Valuation
OTSUKA HOLDINGS CO., LTD. 2.795 %	3,036,000	2.795 %	2 M NT$
DFA Australia Ltd. 0.000893 %	970	0.000893 %	758 NT$

GlycoNex, Inc.

8th Floor, Section 1 No. 97 Xintai 5th Road

221 75, New Taipei

http://www.glyconex.com.tw

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLYCONEX INCORPORATION	-16.30%	83.68M
MODERNA, INC.	+22.81%	46.81B
IQVIA HOLDINGS INC.	-1.88%	41.37B
LONZA GROUP AG	+46.79%	41.29B
CELLTRION, INC.	-6.20%	28.87B
ICON PUBLIC LIMITED COMPANY	+11.33%	26.06B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
MEDPACE HOLDINGS, INC.	+30.73%	12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	12.08B
BIO-TECHNE CORPORATION	-1.43%	11.96B

Other Biotechnology & Medical Research